|Videos|April 5, 2021

Building COVID-19 Vaccine Trust is a Two-Way Street

Vaccine access and new cases are both increasing. An expert discusses earning trust in at-risk communities.

A new research letter highlighting a San Francisco-based survey study highlighted concerning disparities in racial and ethnic likelihood of interest in getting a COVID-19 vaccine.

The findings, which come at a time when COVID-related inequity has been well-defined among differing races and ethnic groups in the US, highlight the historical systemic issue of healthcare inequality among patients.

Investigators reported that Asian and multiracial individuals, and those of other races were more similar to Black and Latinx individuals than White individuals in their likeliness of getting a COVID-19 vaccine.

As people of color and their respective US communities have faced disproportionate burden of the pandemic, inequities in vaccination, investigators wrote, would compound these disparities.

In a Contagion interview regarding these findings, study author Kevin Grumbach, MD, of the Department of Family and Community Medicine at University of California San Francisco, discussed the implication of results at a time when vaccination rollout is peaking in the US, and new cases are again steadily increasing.

“There’s been a really good framework to say we should really talk about our trustworthiness,” Grumbach said. “Have we earned the trust, as people in public health, biomedical research, and healthcare, particularly with communities that have been subject to oppression and even in exploitation in certain biomedical activities?”


Related to this article

Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.